Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 4Nasopharyngeal Carcinoma 3Esophageal Neoplasms 3Colorectal Neoplasms 3Barrett Esophagus 2Urogenital Neoplasms 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Pathologic Complete Response 1Paranasal Sinus Neoplasms 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Lung Neoplasms 1Locally Advanced Pancreatic Cancer 1Jaw Cysts 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Colitis 1Carcinoma, Non-Small-Cell Lung 1Bacteremia 1

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Endoscopy × Clear all
NCT03183115 2023-03-03

RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection

E-DA Hospital

Phase NA Recruiting
100 enrolled
Gastrointestinal

Esophageal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡